P160 Clinical and sociodemographic associates of depression and anxiety in SLE. (26th April 2021)

• Record Type: Journal Article
• Authors: Eldeiry, David F; Zandy, Moe; Tayer-Shifman, Oshrat E; Kwan, Andrew; Marzouk, Sherief; Su, Jiandong; Bingham, Kathleen; Touma, Zahi
• Is Part Of: Rheumatology. Volume 60(2021)Supplement 1
• Publication Date: 2021-04-26
• Subjects: Rheumatism -- Periodicals; Rheumatology -- Periodicals; 616.723005
• DOI: 10.1093/rheumatology/keab247.156
• Languages: English
• ISSNs: 1462-0324

Abstract

Abstract: Background/Aims In our recent systematic review, we have shown a high prevalence for depression (35%) and anxiety (26%) in systemic lupus erythematosus (SLE) . A better understanding of the SLE phenotypic manifestations associated with depression and anxiety may lead to earlier diagnosis and treatment interventions. Our objective is to determine the overall prevalence of anxiety and depression in a cohort of SLE patients, stratified by SLE-implicated organ systems and to study their associations. Methods Patients attending the Toronto Lupus Clinic from August 2017 to January 2019 were studied. Depression and Anxiety were diagnosed with Centre for Epidemiological Studies-Depression Scale (cut-off26), BECK Depression Inventory-II (cut-off18), and the BECK Anxiety Inventory (cut-off19). Disease activity was measured with the SLE Disease Activity Index 2000 (SLEDAI-2K). SLE phenotypic manifestations were stratified based on the organ systems of cumulative 10-year SLEDAI-2K. Separate multivariate logistic regression analyses (for depression [D], anxiety [A], and co-morbid anxiety and depression [AD]) were performed to study the factors associated factors, including age at enrolment, sex, ethnicity, disease duration, inception status (enrolled in the clinic within 1 year of SLE diagnosis), fibromyalgia, and SLE phenotypic manifestations, comparing their significance to the group with neither A or D. Results 341 patients (89.7% female), with mean age 45.917.8 years were studied. The prevalence of A and D in the cohort was 34% and 27% respectively, while 21% of the total cohort was found to have AD. Among the 3 outcome groups, MSK system involvement has a significantly higher prevalence when compared to the group with neither A or D (p-values< 0.05). Skin system involvement was also significantly more prevalent among A, D, and AD groups, in comparison to the normal group. Patients with A had significantly higher odds of skin system involvement compared to the normal group (OR = 1.8; 95% CI: 1.1, 3.0). Patients with D had higher odds of MSK (OR = 1.9; 95% CI: 1.1, 3.5) and skin system involvement (OR = 1.8; 95% CI: 1.04, 3.2) compared to the group with neither A or D. Additionally, the odds of skin system involvement was significantly higher among patients with AD, compared to the group with neither (OR = 2.0, 95% CI: 1.2, 3.9). In all three models, employment and fibromyalgia were also significant. Age at enrolment was significant in the D and AD models, while inception patient status was significant in the D model exclusively. Conclusion SLE phenotypic manifestation, specifically those involving patients' skin or MSK systems, along with fibromyalgia, socio-demographic factors, and inception status were associated with anxiety or depression. Routine patient screening and evaluation, especially among patients with shorter disease duration, for these associated factors may facilitate the diagnosis of these mental health disorders, and allow for more timely diagnosis and intervention strategies. Disclosure D.F. Eldeiry: None. M. Zandy: None. O.E. Tayer-Shifman: None. A. Kwan: None. S. Marzouk: None. J. Su: None. K. Bingham: None. Z. Touma: Grants/research support; Young operating and young investigator salary award of the Arthritis Society, new investigator research grant of Physicians' Services Inc Foundation, the CIORA, Rocca Family, Kaiser Family. Other; The Toronto Lupus Clinic Research Program is supported financially by the University Health Network, the Lou Rocca Family, and the Lupus Foundation of Ontario.